Encore Dermatology
5 Great Valley Parkway
Suite 200
Malvern
Pennsylvania
19355
United States
Tel: 844-848-6543
Website: http://www.encorederm.com/
About Encore Dermatology
Headquartered in Malvern, Pennsylvania, Encore Dermatology, Inc. is a privately held fully-integrated dermatology company with a mission committed to delivering innovative prescription therapies and medical devices to dermatologists focusing on customer service and improving the quality-of-life of patients.YEAR FOUNDED:
2015
LEADERSHIP:
CEO: Robert (Bob) J. Moccia
Executive VP, Business Operations: Boris Meyerson, Ph.D.
VP, Marketing: Kent Taylor
VP, Sales: Tim Waite
Controller: Chris Lesovitz
PRODUCTS
Please click here for Encore Dermatology's products.
CAREER:
Please click here for Encore Dermatology's job opportunities.
6 articles about Encore Dermatology
-
Horizon Technology Finance Provides $20 Million Venture Loan Facility to Encore Dermatology
4/8/2019
Horizon Technology Finance Corporation, a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and cleantech industries, announced today it has provided a $20 million venture loan facility to Encore Dermatology, Inc., of which $15 million has been initially funded.
-
Encore Dermatology Inc. Acquires SERNIVO®, TRIANEX® and PROMISEB®
4/2/2019
Encore Dermatology announced today that it has acquired rights for SERNIVO® (betamethasone dipropionate) Spray, 0.05%, as well as rights to market and distribute TRIANEX® 0.05% (Triamcinolone Acetonide Ointment, USP) and PROMISEB® Topical Cream in the United States from Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), through its wholly owned subsidiary Promius Pharma LLC.
-
Encore Dermatology Inc. Announces Results From Pivotal Study Evaluating Impoyz™ (clobetasol propionate) Cream, 0.025% for the Treatment of Moderate to Severe Plaque Psoriasis
1/30/2019
The announcement was made at the 15th annual Maui Derm Conference, that Impoyz Cream demonstrated efficacy early, with 14.2% of Impoyz patients achieving treatment success at day 8 versus 1.6% in the vehicle group.
-
Encore Dermatology, Inc. Announces Phase 2 Safety Data Demonstrating Lower Systemic Drug Exposure With Impoyz™ (clobetasol propionate) Cream, 0.025% Compared to Temovate® (clobetasol propionate) Cream, 0.05%
11/27/2018
Both treatment groups evidenced similar improvements in global psoriasis severity as measured by improvements in the Investigator’s Global Assessment (IGA) from baseline to Day 15.
-
Encore Dermatology Inc. Announces the Launch of IMPOYZTM (clobetasol propionate) Cream, 0.025%, a Newly Formulated High-Potency Topical Corticosteroid
5/1/2018
IMPOYZ Cream is the only FDA-approved high-potency topical corticosteroid with 0.025% clobetasol propionate.
-
Dr. Reddy's Laboratories Ltd. Announces The Out-Licensing Of DFD-06 To Encore Dermatology
8/22/2017